Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease

Base to Base Biotech por Jim Cornall

Notas del episodio

On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director of oncology at CureLab Oncology Inc., about elanagen, a promising therapeutic advance for women with platinum-resistant ovarian cancer; Eden Ben, CEO of Amorphical, about nano-amorphous mineral therapeutics inspired by blue crayfish; and Hans Schambye, CEO of BOOST Pharma, a company making progress in the battle with brittle bone disease.

Times:

03:36 Amorphical

26:26 CureLab Oncology

43:31 BOOST Pharma

CureLab Oncology

CureLab Oncology Inc. is a clinical-stage biotechnology company headquartered in the greater Boston area. The company is focused on dev ... 

 ...  Leer más
Palabras clave
biotechbiotechnologycanceroncologybrittle bone diseasemineral therapeuticsBOOST Pharmacell therapyAmorphicalCureLab Oncology